WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 20'5301 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 29'2141 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 10'372  10'418  10'471  10'528  10'582  10'355  9'953  9'805 
Births 81  83  85  88  91  113  114  160 
Surviving infants 81  83  85  88  91  113  113  156 
Pop. less than 5 years 431  442  453  464  475  535  569  811 
Pop. less than 15 years 1'438  1'467  1'493  1'520  1'546  1'660  2'043  2'527 
Female 15-49 years 2'369  2'399  2'432  2'465  2'497  2'637  2'477  2'370 

Number of reported cases

(Click for retrospective incidence data for Portugal)
Diphtheria
ChartChart
  90 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  23  45  407 
Mumps
ChartChart
  162  158  6'493 
Pertussis
ChartChart
  230  73  103  224  22  101  71 
Polio*
ChartChart
 
Rubella
ChartChart
  58 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  15  34  73 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Portugal)
Vaccine year result method % card seen                                                
BCG          32  99  99  99  82  88 
DTP1          99 
DTP3          98  98  98  98  96  89  73 
DTP4          96  96 
IPV1         
HepB_BD          97  98  98  97  64 
HepB3          98  98  98  98  58 
Hib3          98  98  98  98  86 
JapEnc         
MCV1          98  98  98  97  87  85  54 
MCV2          95  96  96  96  49 
MenA         
PCV1          80 
PCV2         
PCV3         
Pol3          98  98  98  98  96  89  18 
Rota1         
RotaC         
RCV1          98  98  98  97 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Portugal)
BCG
ChartChart
  32  32  99  99  99  82  88 
DTP1
ChartChart
  99  99  99  99  99  99  96  90 
DTP3
ChartChart
  98  98  98  98  98  96  89  73 
HepB3
ChartChart
  98  98  98  98  98  58 
HepB_BD
ChartChart
  97  97  98  98  97  64 
Hib3
ChartChart
  98  98  98  98  98  86 
MCV1
ChartChart
  98  98  98  98  97  87  85  54 
MCV2
ChartChart
  95  95  96  96  96  48 
PCV3
 
Pol3
ChartChart
  98  98  98  98  98  96  89  18 
RCV1
ChartChart
  98  98  98  98  97  87  85 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHib 18 months; Yes
DTaPHibIPV 2, 4, 6 months; Yes
DTaPIPV 5-6 years; Yes
HepB_Adult Yes specific groups, health care workers
HepB_Pediatric birth; 2, 6 months; Yes
HPV 10-13 years, +6 months; Yes
Influenza_Adult >= 65 years Yes and pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MenC_conj 12 months; Yes
MMR 12 months; 5-6 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps Yes specific risk groups
Td 10-13 years; Yes every 10 years

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2'015  Continuous    continuous  continuous  continuous 
Nº of districts with microplans that include activities to raise immunization coverage number    

System performance

Total Nº districts in country number    
Nº districts with DTP3 coverage >=80% number  
% of districts with DTP3 coverage >=80% From 0 to 100%   100    100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number  
% of districts with MCV1 coverage >=95% From 0 to 100%   100    86  71  86  71 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%       100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.